Fresenius Medical Care AG & Co. KGaA $FMS Shares Sold by Cresset Asset Management LLC

Cresset Asset Management LLC cut its holdings in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 24.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 15,433 shares of the company’s stock after selling 4,967 shares during the period. Cresset Asset Management LLC’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $384,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the company. Pzena Investment Management LLC lifted its stake in Fresenius Medical Care AG & Co. KGaA by 0.6% during the first quarter. Pzena Investment Management LLC now owns 15,377,090 shares of the company’s stock worth $382,890,000 after purchasing an additional 94,065 shares in the last quarter. Millennium Management LLC lifted its stake in Fresenius Medical Care AG & Co. KGaA by 5,297.5% during the fourth quarter. Millennium Management LLC now owns 722,238 shares of the company’s stock worth $16,351,000 after purchasing an additional 708,857 shares in the last quarter. Integral Health Asset Management LLC lifted its stake in Fresenius Medical Care AG & Co. KGaA by 33.3% during the fourth quarter. Integral Health Asset Management LLC now owns 600,000 shares of the company’s stock worth $13,584,000 after purchasing an additional 150,000 shares in the last quarter. Todd Asset Management LLC acquired a new position in Fresenius Medical Care AG & Co. KGaA during the first quarter worth $12,009,000. Finally, Northern Trust Corp lifted its stake in Fresenius Medical Care AG & Co. KGaA by 45.9% during the fourth quarter. Northern Trust Corp now owns 362,190 shares of the company’s stock worth $8,200,000 after purchasing an additional 113,953 shares in the last quarter. 8.37% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have commented on FMS. Zacks Research cut Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 18th. Wall Street Zen upgraded Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research note on Friday. Truist Financial upped their price target on Fresenius Medical Care AG & Co. KGaA from $25.00 to $30.00 and gave the stock a “hold” rating in a research note on Monday, May 12th. Finally, Morgan Stanley restated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, August 12th. One equities research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $27.80.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Fresenius Medical Care AG & Co. KGaA stock opened at $25.5750 on Monday. Fresenius Medical Care AG & Co. KGaA has a twelve month low of $18.94 and a twelve month high of $30.46. The stock’s fifty day simple moving average is $26.41 and its 200-day simple moving average is $25.82. The company has a quick ratio of 1.08, a current ratio of 1.44 and a debt-to-equity ratio of 0.44.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.50 by $0.02. Fresenius Medical Care AG & Co. KGaA had a return on equity of 6.75% and a net margin of 3.39%.The business had revenue of $5.54 billion for the quarter, compared to analyst estimates of $5 billion. On average, analysts expect that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current year.

Fresenius Medical Care AG & Co. KGaA Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.